Meeting
2018 ASCO Annual Meeting
A phase 1/2, multicenter, dose-escalation and expansion study of combination therapy with venetoclax, daratumumab, and dexamethasone (with and without bortezomib) in subjects with relapsed or refractory multiple myeloma.
Authors
Orlando Bueno
AbbVie Inc., North Chicago, IL
Orlando Bueno , Rachel Slimp , Michelle Jacobson , John Carl Pesko , Hong Li , Jeremy A. Ross , Kevin Freise , Paulo Cesar Maciag
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Hematologic Malignancies—Plasma Cell Dyscrasia
Track
Hematologic Malignancies—Plasma Cell Dyscrasia
Sub Track
Multiple Myeloma
Clinical Trial Registration Number
NCT03314181
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS8061)
DOI
10.1200/JCO.2018.36.15_suppl.TPS8061
Abstract #
TPS8061
Poster Bd #
67a
Abstract Disclosures
Similar Posters
Poster
2015 ASCO Annual Meeting
Phase 1b interim results: Venetoclax (ABT-199/GDC-0199) in combination with bortezomib (BTZ) and dexamethasone (Dex) in relapsed/refractory (R/R) multiple myeloma (MM).
First Author: Cyrille Touzeau
Poster
2023 ASCO Annual Meeting
OMNIA-2: Phase I/II study of ANV419, an IL-2R-βγ targeted antibody-IL-2 fusion protein, in patients with relapsed or refractory multiple myeloma.
First Author: Dagmar Hess
Poster
2020 ASCO Virtual Scientific Program
Efficacy and safety of carfilzomib, dexamethasone, daratumumab (KdD) twice-weekly at 56 mg/m2 and once-weekly at 70 mg/m2 in relapsed or refractory multiple myeloma (RRMM): Cross-study comparison of candor and MMY1001.
First Author: Xavier Leleu
Poster
2020 ASCO Virtual Scientific Program
Updated analysis of a phase I/II study of venetoclax in combination with daratumumab and dexamethasone, +/- bortezomib, in patients with relapsed/refractory multiple myeloma.
First Author: Jonathan L. Kaufman